Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells 77,705 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 77,705 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $16.39, for a total transaction of $1,273,584.95. Following the completion of the sale, the general counsel now owns 125,785 shares in the company, valued at $2,061,616.15. This represents a 38.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Centessa Pharmaceuticals Stock Down 6.2 %

Centessa Pharmaceuticals stock opened at $16.51 on Thursday. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -10.79 and a beta of 1.52. Centessa Pharmaceuticals plc has a 52-week low of $6.65 and a 52-week high of $18.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The firm has a 50 day moving average price of $16.58 and a two-hundred day moving average price of $13.49.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Guggenheim raised their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. B. Riley initiated coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. Jefferies Financial Group raised their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. BMO Capital Markets boosted their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Finally, Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $25.83.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC lifted its stake in Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after buying an additional 1,509 shares during the period. Quarry LP boosted its holdings in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after buying an additional 3,108 shares in the last quarter. Sandia Investment Management LP acquired a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth approximately $90,000. Finally, Fred Alger Management LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth approximately $99,000. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.